Adriamycin 50 mg
Adriamycin 50mg Injection is an anti-cancer medication. It works by suppressing the activity of an enzyme (topoisomerase II) involved in DNA multiplication of the cancer cells. It also forms harmful chemicals (free radicals) which cause DNA damage. This slows the growth of cancer cells and eventually kills them
Related products
-
Farmorubicin Inj.10mg.
0 out of 5(0)Farmorubicin RD 10mg Injection is used in the treatment of various types of cancers of blood, breast, stomach, lung, ovaries and soft tissues. It also helps to prevent the recurrence of bladder cancer after surgery.
Login To See PriceCompare -
Alimta Inj.500mg.
0 out of 5(0)ALIMTA is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
Login To See PriceCompare -
Decapeptyldepot 3.75 mg Inj.
0 out of 5(0)Decapeptyl Depot Injection is used in the treatment of prostate cancer. It is also used to treat endometriosis (endometrium of uterus grows excessively and causes symptoms like pain, heavy or irregular periods), and central precocious puberty (very early puberty).
Login To See PriceCompare -
Ristova 100 mg injection
0 out of 5(0)Ristova 100 mg Injection is an anticancer medicine that is used alone or in a combination with other medicines for the treatment of various types of blood cancers. It is also used for the treatment of autoimmune diseases such as rheumatoid arthritis, microscopic polyangitis, Wegener’s granulomatosis etc.
Login To See PriceCompare -
Velcade 3.5 mg
0 out of 5(0)Velcade is a prescription medicine used to treat the symptoms of Mantle Cell Lymphoma and Multiple Myeloma. Velcade may be used alone or with other medications. Velcade belongs to a class of drugs called Antineoplastics, Proteasome Inhibitors. It is not known if Velcade is safe and effective in children.
Login To See PriceCompare
Reviews
There are no reviews yet.